MAML2基因表达及临床参数与低级别胶质瘤(LGG)患者的诊断及预后价值

Diagnostic and prognostic value of MAML2 gene expression and clinical parameters in low⁃grade gliomas

脑胶质瘤(Glioma)是最常见的中枢系统恶性肿瘤,MAML2是NOTCH信号通路的共激活因子,通过癌基因组数据库(TCGA)分析验证MAML2基因表达及相关临床参数与低级别胶质瘤(LGG)的诊断及预后价值。从癌基因数据库LGG数据库中下载患者基因表达量数据及患者临床数据,采用统计学方法验证MAML2基因表达差异及临床参数与胶质瘤的诊断与预后关系。在TCGA LGG队列中,发现LGG组织中的MAML2基因较正常组织明显上调(P<0.001),其差异表达可作为低级别胶质瘤的潜在诊断标志物。同时,MAML2低表达组的LGG患者总体生存率低于高表达组(P=0.0052)。此外,单因素多因素分析提示肿瘤分级,初治后肿瘤再发事件及MAML2低表达是低级别胶质瘤患者的独立危险因素。研究结果表明MAML2基因有可能成为诊断及预测低级别胶质瘤的一个潜在分子标记物。

Gliomas are the most common malignant tumors of the central system.MAML2 is a co⁃activator of the NOTCH signaling pathway.This study aimed to verify the diagnostic and prognostic value of MAML2 gene expression and clinical parameters in low⁃grade glioma(LGG).First,the gene expression data and clinical data of patients were downloaded from TCGA LGG database,and statistical methods were used to verify the difference of MAML2 gene expression as well as the relationship between clinical parameters and the diagnosis and prognosis of LGGs.In the TCGA LGG cohort,it was found that the expression of MAML2 gene in LGG was significantly higher than that in the normal tissues(P<0.001),whose differential expression could be used as potential diagnostic marker for LGG.Meanwhile,the overall survival rate of LGG patients in the low expression group of MAML2 was lower than that in the high expression group(P=0.0052).In addition,univariate and multivariate analyses suggested that tumor grade,recurrence,and low expression of MAML2 were independent risk factors for LGGs.The results of this study suggest that MAML2 gene may be a potential molecular marker for the diagnosis and prediction of LGGs,but further experiments are needed.